Astellas Pharma Inc. (ALPMF)
| Previous close | 11.10 |
| Open | 12.00 |
| Bid | 11.80 x 45900 |
| Ask | 11.80 x 40000 |
| Day's range | 12.00 - 12.00 |
| 52-week range | 9.13 - 13.03 |
| Volume | |
| Avg. volume | 2,379 |
| Market cap | 21.478B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 150.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.48 (3.97%) |
| Ex-dividend date | 31 Mar 2025 |
| 1y target est | N/A |
- PR Newswire
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS). The EFS will evaluate the safety and feasibility of an investigational implantable device designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder
- PR Newswire
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause, will be featured in four oral and two poster presentations during the International Menopause Society (IMS) 19th World Congress on Menopause in Melbourne, Australia, October 19-22. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.1,2
- PR Newswire
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
AviadoBio Ltd. ("AviadoBio") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations (FTD-GRN).
